Drug Patents Expiring in 2041

1. List of Airduo Digihaler drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11173259

(Pediatric)

TEVA PHARM Drug delivery device with electronics and power management
Jan, 2041

(17 years from now)

US11266796 TEVA PHARM Inhalation device with integrated electronics
Feb, 2041

(18 years from now)

US11266796

(Pediatric)

TEVA PHARM Inhalation device with integrated electronics
Aug, 2041

(18 years from now)

Exclusivity Exclusivity Expiration
M Jul 9, 2024
Pediatric Exclusivity (PED) Jan 9, 2025

Drugs and Companies using FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE ingredient

Market Authorisation Date: 27 January, 2017

Treatment: NA

Dosage: POWDER;INHALATION

More Information on Dosage

2. List of Armonair Digihaler drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11173259

(Pediatric)

TEVA PHARM Drug delivery device with electronics and power management
Jan, 2041

(17 years from now)

US11266796 TEVA PHARM Inhalation device with integrated electronics
Feb, 2041

(18 years from now)

US11266796

(Pediatric)

TEVA PHARM Inhalation device with integrated electronics
Aug, 2041

(18 years from now)

Exclusivity Exclusivity Expiration
New Patient Population (NPP) Jul 9, 2024
New Strength (NS) Jul 9, 2024
Pediatric Exclusivity (PED) Jan 9, 2025

Drugs and Companies using FLUTICASONE PROPIONATE ingredient

Market Authorisation Date: 27 January, 2017

Treatment: NA

Dosage: POWDER;INHALATION

More Information on Dosage

3. List of Dapzura Rt drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11173189 BAXTER HLTHCARE CORP Daptomycin formulations containing a combination of sorbitol and mannitol
Mar, 2041

(18 years from now)

Drugs and Companies using DAPTOMYCIN ingredient

Market Authorisation Date: 25 January, 2022

Treatment: Method of treating a bacterial infection by administering a reconstituted solid formulation of daptomycin containing 31.0 to 59.4% wt total mannitol and sorbitol

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

4. List of Epidiolex drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11406623 GW RES LTD Methods of treating tuberous sclerosis complex with cannabidiol and everolimus
Mar, 2041

(18 years from now)

US11160795 GW RES LTD Methods of treating tuberous sclerosis complex with cannabidiol and everolimus
Mar, 2041

(18 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Sep 28, 2023
Orphan Drug Exclusivity (ODE) Jul 31, 2027
New Patient Population (NPP) Jul 31, 2023

Drugs and Companies using CANNABIDIOL ingredient

NCE-1 date: September, 2022

Market Authorisation Date: 28 September, 2018

Treatment: Use for the treatment of seizures associated with tuberous sclerosis complex in patients taking everolimus

Dosage: SOLUTION;ORAL

How can I launch a generic of EPIDIOLEX before it's patent expiration?
More Information on Dosage

5. List of Exparel drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11426348 PACIRA PHARMS INC Compositions of bupivacaine multivesicular liposomes
Jan, 2041

(17 years from now)

US11452691 PACIRA PHARMS INC Compositions of bupivacaine multivesicular liposomes
Jan, 2041

(17 years from now)

US11357727 PACIRA PHARMS INC Manufacturing of bupivacaine multivesicular liposomes
Jan, 2041

(17 years from now)

US11311486 PACIRA PHARMS INC Manufacturing of bupivacaine multivesicular liposomes
Jan, 2041

(17 years from now)

US11304904 PACIRA PHARMS INC Manufacturing of bupivacaine multivesicular liposomes
Jan, 2041

(17 years from now)

US11033495 PACIRA PHARMS INC Manufacturing of bupivacaine multivesicular liposomes
Jan, 2041

(17 years from now)

US11179336 PACIRA PHARMS INC Manufacturing of bupivacaine multivesicular liposomes
Jan, 2041

(17 years from now)

US11278494 PACIRA PHARMS INC Manufacturing of bupivacaine multivesicular liposomes
Jan, 2041

(17 years from now)

Exclusivity Exclusivity Expiration
New Patient Population (NPP) Mar 22, 2024

Drugs and Companies using BUPIVACAINE ingredient

Market Authorisation Date: 28 October, 2011

Treatment: Method of treating pain, for example, via infiltration for local analgesia or via interscalene brachial plexus nerve block for regional analgesia; Method of treating pain, for example, via infiltration for local analgesia or via nerve block, for example, nterscalene brachial plexus for regional analgesia; Method of treating pain, for example, treating postsurgical pain via infiltration for local analgesia or via interscalene brachial plexus nerve block for regional analgesia; Method of providing local or regional analgesia via infiltration for local analgesia or via interscalene brachial plexus nerve block or femoral nerve block for regional analgesia; Method of providing postsurgical pain management, for example, via infiltration for local analgesia or via interscalene brachial plexus nerve block for regional analgesia

Dosage: INJECTABLE, LIPOSOMAL;INJECTION

How can I launch a generic of EXPAREL before it's patent expiration?
More Information on Dosage

6. List of Invega Hafyera drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11304951 JANSSEN PHARMS Dosing regimens associated with extended release paliperidone injectable formulations
May, 2041

(18 years from now)

US11324751 JANSSEN PHARMS Dosing regimens associated with extended release paliperidone injectable formulations
May, 2041

(18 years from now)

Exclusivity Exclusivity Expiration
New Strength (NS) Aug 30, 2024

Drugs and Companies using PALIPERIDONE PALMITATE ingredient

Market Authorisation Date: 18 May, 2015

Treatment: Reinitiation of schizophrenia treatment wherein more than 6 months 3 weeks but less than 8 months have elapsed since the last dose; Treatment of schizophrenia by administering a dose up to two weeks before or three weeks after the scheduled six-month dose

Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

How can I launch a generic of INVEGA HAFYERA before it's patent expiration?
More Information on Dosage

7. List of Lyvispah drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11491125 AMNEAL Baclofen formulations and methods of minimizing patient exposure to metabolite variations
Sep, 2041

(18 years from now)

Drugs and Companies using BACLOFEN ingredient

Market Authorisation Date: 22 November, 2021

Treatment: Treatment of spasticity resulting from multiple sclerosis, particularly for the relief of flexor spasms and concomitant pain, clonus, and muscular rigidity; Treatment of spasticity resulting from spinal cord injuries and other spinal cord diseases

Dosage: GRANULES;ORAL

More Information on Dosage

8. List of Norliqva drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11458095 CMP DEV LLC NA
Feb, 2041

(18 years from now)

US11253474 CMP DEV LLC Pharmaceutical solution of amlodipine
Feb, 2041

(18 years from now)

Drugs and Companies using AMLODIPINE BESYLATE ingredient

Market Authorisation Date: 24 February, 2022

Treatment: Norliqva is indicated for the treatment of hypertension, to lower blood pressure in adults and children 6 years of age and older; Norliqva is indicated for the symptomatic treatment of chronic stable angina; Norliqva is indicated for the treatment of confirmed or suspected vasospastic angina

Dosage: SOLUTION;ORAL

More Information on Dosage

9. List of Posimir drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11400019 INNOCOLL Sustained release drug delivery systems with reduced impurities and related methods
Jan, 2041

(17 years from now)

Exclusivity Exclusivity Expiration
New Product (NP) Feb 1, 2024

Drugs and Companies using BUPIVACAINE ingredient

Market Authorisation Date: 01 February, 2021

Treatment: NA

Dosage: SOLUTION, EXTENDED RELEASE;INFILTRATION

More Information on Dosage

10. List of Proair Digihaler drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11266796 TEVA BRANDED PHARM Inhalation device with integrated electronics
Feb, 2041

(18 years from now)

Drugs and Companies using ALBUTEROL SULFATE ingredient

Market Authorisation Date: 31 March, 2015

Treatment: NA

Dosage: POWDER, METERED;INHALATION

More Information on Dosage

11. List of Tlando drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11464735 ANTARES PHARMA INC Fixed dose oral testosterone undecanoate compositions and use thereof
Apr, 2041

(18 years from now)

Exclusivity Exclusivity Expiration
New Product (NP) Mar 28, 2025

Drugs and Companies using TESTOSTERONE UNDECANOATE ingredient

Market Authorisation Date: 28 March, 2022

Treatment: Testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone; Primary hypogonadism (congenital or acquired); Hypogonadotropic hypogonadism (congenital or acquired).

Dosage: CAPSULE;ORAL

More Information on Dosage

12. List of Veklury drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11491169 GILEAD SCIENCES INC Remdesivir treatment methods
May, 2041

(18 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Oct 22, 2025
New Patient Population (NPP) Apr 25, 2025
New Dosing Schedule (D) Jan 21, 2025

Drugs and Companies using REMDESIVIR ingredient

NCE-1 date: October, 2024

Market Authorisation Date: 22 October, 2020

Treatment: Treatment of coronavirus disease 2019 (covid-19) in adults and pediatric patients (at least 28 days of age and 3 kg) requiring hospitalization and for whom concomitant use of chloroquine, or an analog or sale thereof, is not recommended; Treatment of coronavirus disease 2019 (covid-19) in non-hospitalized adults and pediatric patients (at least 28 days of age and 3 kg) and for whom concomitant use of chloroquine, or an analog or salt thereof, is not recommended

Dosage: POWDER;INTRAVENOUS; SOLUTION;INTRAVENOUS

More Information on Dosage

13. List of Wegovy drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11318191 NOVO GLP-1 compositions and uses thereof
Feb, 2041

(18 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Dec 5, 2022
New Product (NP) Jun 4, 2024

Drugs and Companies using SEMAGLUTIDE ingredient

NCE-1 date: December, 2021

Market Authorisation Date: 04 June, 2021

Treatment: Method for weight management

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in